Clinical development of Modified Vaccinia virus Ankara vaccines.

Clinical development of Modified Vaccinia virus Ankara vaccines.

Show other versions (1)

The smallpox vaccine Vaccinia was successfully used to eradicate smallpox, but although very effective, it was a very reactogenic vaccine and responsible for the deaths of one or two people per million vaccinated. Modified Vaccinia virus Ankara (MVA) is a replication-deficient and attenuated derivat...

Descrición completa

Detalles Bibliográficos
Autor Principal:	Gilbert, S
Formato:	Journal article
Idioma:	English
Publicado:	2013

Títulos similares

Clinical development of Modified Vaccinia virus Ankara vaccines
por: Gilbert, S
Publicado: (2013)

Development of Modified Vaccinia Virus Ankara-Based Vaccines: Advantages and Applications
por: Olga Vladimirovna Orlova, et al.
Publicado: (2022-09-01)

Ty virus-like particles, DNA vaccines and Modified Vaccinia Virus Ankara; comparisons and combinations.
por: Gilbert, S, et al.
Publicado: (1999)

Safety and immunogenicity of DNA/modified vaccinia virus ankara malaria vaccination in African adults.
por: Moorthy, V, et al.
Publicado: (2003)

Modified Vaccinia virus Ankara-based vaccines in the era of personalized immunotherapy of cancer
por: Kaïdre Bendjama, et al.
Publicado: (2017-09-01)

Elements in the Development of a Production Process for Modified Vaccinia Virus Ankara
por: Volker Sandig, et al.
Publicado: (2013-11-01)

Modified Vaccinia Virus Ankara as a Viral Vector for Vaccine Candidates against Chikungunya Virus
por: Juan García-Arriaza, et al.
Publicado: (2021-08-01)

Rapid Development of Modified Vaccinia Virus Ankara (MVA)-Based Vaccine Candidates Against Marburg Virus Suitable for Clinical Use in Humans
por: Alina Tscherne, et al.
Publicado: (2024-11-01)

Assessment of immunogenicity and efficacy of a Zika vaccine using modified vaccinia Ankara virus as carriers
por: López-Camacho, C, et al.
Publicado: (2019)

New approaches for improving the immunogenicity of modified vaccinia virus Ankara as a recombinant vaccine vector
por: Alharbi, N
Publicado: (2014)

Assessment of Immunogenicity and Efficacy of a Zika Vaccine Using Modified Vaccinia Ankara Virus as Carriers
por: César López-Camacho, et al.
Publicado: (2019-11-01)

Improved Host Range Selection for Recombinant Modified Vaccinia Virus Ankara
por: Caroline Staib, et al.
Publicado: (2003-04-01)

Ebola virus – prospects for a novel virus-like-particle-expressing modified vaccinia Ankara-based vaccine
por: Harriet L. Robinson, et al.
Publicado: (2018-09-01)

Enhanced T-cell immunogenicity of plasmid DNA vaccines boosted by recombinant modified vaccinia virus Ankara in humans.
por: McConkey, S, et al.
Publicado: (2003)

Safety and immunogenicity of novel recombinant BCG and modified vaccinia virus Ankara vaccines in neonate rhesus macaques.
por: Rosario, M, et al.
Publicado: (2010)

Synthetic modified vaccinia Ankara vaccines confer cross-reactive and protective immunity against mpox virus
por: Flavia Chiuppesi, et al.
Publicado: (2024-02-01)

The third generation modified vaccinia Ankara vaccine is effective in preventing the transmission of mpox
por: Mingwang Shen, et al.
Publicado: (2024-10-01)

Deletion of fifteen open reading frames from modified vaccinia virus Ankara fails to improve immunogenicity
por: Alharbi, N, et al.
Publicado: (2015)

Transient Host Range Selection for Genetic Engineering of Modified Vaccinia Virus Ankara
por: C. Staib, et al.
Publicado: (2000-06-01)

Hazard Characterization of Modified Vaccinia Virus Ankara Vector: What Are the Knowledge Gaps?
por: Malachy I. Okeke, et al.
Publicado: (2017-10-01)

Deletion of Fifteen Open Reading Frames from Modified Vaccinia Virus Ankara Fails to Improve Immunogenicity.
por: Naif Khalaf Alharbi, et al.
Publicado: (2015-01-01)

Safety of DNA and modified vaccinia virus Ankara vaccines against liver-stage P. falciparum malaria in non-immune volunteers.
por: Moorthy, V, et al.
Publicado: (2003)

Safety of DNA and modified vaccinia virus Ankara vaccines against liver-stage P. falciparum malaria in non-immune volunteers
por: Moorthy, V, et al.
Publicado: (2003)

Cardiac Safety in Clinical Trials with Preventive HIV Vaccine Candidates Based on Modified Vaccinia Ankara (MVA)
por: Schmidt, C, et al.
Publicado: (2008)

Dendritic cells infected by recombinant modified vaccinia virus Ankara retain immunogenicity in vivo despite in vitro dysfunction.
por: Behboudi, S, et al.
Publicado: (2004)

Enhanced immunogenicity for CD8+ T cell induction and complete protective efficacy of malaria DNA vaccination by boosting with modified vaccinia virus Ankara.
por: Schneider, J, et al.
Publicado: (1998)

Recombinant modified vaccinia virus Ankara efficiently restimulates human cytotoxic T lymphocytes in vitro.
por: Dorrell, L, et al.
Publicado: (2000)

Low Immune Cross-Reactivity between West Nile Virus and a Zika Virus Vaccine Based on Modified Vaccinia Virus Ankara
por: Nereida Jiménez de Oya, et al.
Publicado: (2022-03-01)

Immunogenicities of intravenous and intramuscular administrations of modified vaccinia virus Ankara-based multi-CTL epitope vaccine for human immunodeficiency virus type 1 in mice.
por: Hanke, T, et al.
Publicado: (1998)

Recombination-mediated genetic engineering of a bacterial artificial chromosome clone of modified vaccinia virus Ankara (MVA).
por: Cottingham, M, et al.
Publicado: (2008)

Genome Sequencing of a Camelpox Vaccine Reveals Close Similarity to Modified <i>Vaccinia virus</i> Ankara (MVA)
por: Maurilia Marcacci, et al.
Publicado: (2020-07-01)

Heat-inactivated modified vaccinia virus Ankara boosts Th1 cellular and humoral immunity as a vaccine adjuvant
por: Ning Yang, et al.
Publicado: (2022-10-01)

Immune responses to novel adenovirus type 26 and modified vaccinia virus Ankara-vectored ebola vaccines at 1 year
por: Winslow, R, et al.
Publicado: (2017)

Recombination-mediated genetic engineering of a bacterial artificial chromosome clone of modified vaccinia virus Ankara (MVA).
por: Matthew G Cottingham, et al.
Publicado: (2008-02-01)

Expanding the repertoire of Modified Vaccinia Ankara-based vaccine vectors via genetic complementation strategies.
por: David A Garber, et al.
Publicado: (2009-01-01)

Phase 2a safety and immunogenicity testing of DNA and recombinant modified vaccinia ankara virus vaccines expressing virus-like particles
por: Goepfert P, et al.
Publicado: (2012-09-01)

Therapeutic vaccination against hepatitis B virus using heterolgous prime boost strategy with DNA and modified vaccinia virus ankara vectors
por: McConkey, S, et al.
Publicado: (2003)

Modified vaccinia virus Ankara exerts potent immune modulatory activities in a murine model.
por: Miriam Nörder, et al.
Publicado: (2010-01-01)

Enhanced immunogenicity of CD4(+) t-cell responses and protective efficacy of a DNA-modified vaccinia virus Ankara prime-boost vaccination regimen for murine tuberculosis.
por: Mcshane, H, et al.
Publicado: (2001)

Clinical experience with plasmid DNA- and modified vaccinia virus Ankara-vectored human immunodeficiency virus type 1 clade A vaccine focusing on T-cell induction.
por: Hanke, T, et al.
Publicado: (2007)